Streetbeat News

Earnings

MYRG

MYR Group shares rose following a strong Q3 EPS report and a positive analyst rating from Baird, which increased its price target from $131 to $138.

Portfolio Pulse from Benzinga Newsdesk

October 31, 2024 | 6:53 pm

PLSE

Pulse Biosciences shares declined following the announcement of a year-over-year decrease in Q3 EPS results.

Portfolio Pulse from Benzinga Newsdesk

October 31, 2024 | 6:51 pm

NVRI

Enviri's shares dropped following disappointing Q3 results and lower-than-expected Q4 and FY24 EPS guidance.

Portfolio Pulse from Benzinga Newsdesk

October 31, 2024 | 6:50 pm

ATEC

AUR

CMPS

LMND

MTNB

ROOT

UBER

U.S. stocks fell with the Nasdaq down 500 points. Uber shares dropped over 10% despite beating earnings expectations. Root, Alphatec, and Lemonade saw significant gains after positive earnings reports, while Matinas BioPharma, Aurora Innovation, and COMPASS Pathways experienced sharp declines.

Portfolio Pulse from Avi Kapoor

October 31, 2024 | 6:43 pm

GCI

Gannett's shares have declined following the release of disappointing Q3 financial results.

Portfolio Pulse from Benzinga Newsdesk

October 31, 2024 | 6:43 pm

MDXG

MiMedx Group shares rose following the release of their Q3 financial results, which exceeded expectations.

Portfolio Pulse from Benzinga Newsdesk

October 31, 2024 | 6:42 pm

SXC

SunCoke Energy shares rose following the release of their Q3 financial results, which exceeded expectations.

Portfolio Pulse from Benzinga Newsdesk

October 31, 2024 | 6:40 pm

ANIK

Anika Therapeutics shares declined following the release of disappointing Q3 financial results.

Portfolio Pulse from Benzinga Newsdesk

October 31, 2024 | 6:36 pm

CVX

Chevron (CVX) is set to release its Q3 earnings, with investors keen on its handling of volatile oil prices and structural changes. In Q2, Chevron exceeded revenue expectations but missed earnings estimates due to lower refining margins and international sales. The company is expanding globally and relocating its headquarters to Houston. Chevron's Q3 report will be crucial for insights into its production growth and market strategies.

Portfolio Pulse from Henry Khederian

October 31, 2024 | 6:31 pm

CMPS

Compass Pathways (CMPS) faces delays in its Phase 3 psilocybin trials, leading to a 30% workforce reduction to conserve cash. The company aims to focus on its COMP360 program for treatment-resistant depression, with trial data now expected in 2025 and 2026. Shares fell 23.02% following the announcement.

Portfolio Pulse from Juan Spínelli

October 31, 2024 | 6:30 pm